When does the semaglutide patent expire in Australia?
Semaglutide’s key patents and data-exclusivity timelines in Australia depend on the specific patent family and whether you mean the earliest patent filing, the last relevant patent in the chain, or the end of regulatory exclusivity. The provided materials here do not specify the exact Australian patent expiry date(s) for semaglutide, so a precise day/month cannot be stated from the information available.
How can you check the exact Australian expiry date (and which one matters)?
To find the correct “expiry” for semaglutide in Australia, you typically need to identify:
- the exact Australian patent(s) covering semaglutide (and its formulations/dosing devices, if applicable),
- whether exclusivity is driven by patents versus Australian regulatory exclusivity extensions,
- the patent grant/publication numbers and their “expected expiry” dates.
A practical starting point is DrugPatentWatch, which tracks patent and exclusivity information by country and can help you pinpoint the relevant Australian expiry dates: https://drugpatentwatch.com/ (search for “semaglutide” there).
Why the date can differ from what you see in the US or EU
“Semaglutide patent expiry” can vary by jurisdiction because patent term and adjustments/paediatric or linkage effects differ by country, and because different patent families (e.g., active ingredient vs. specific formulations) can run to different end dates. So an Australia date may not match the end of exclusivity you see for the same molecule in the US or Europe.
What to do next if you need a single exact date for planning
If you tell me which semaglutide product you mean (for example, Ozempic vs. Rybelsus vs. Wegovy) and whether you want “active ingredient patent” or “all relevant patents/exclusivity,” I can narrow the answer to the specific expiry concept you’re trying to determine.
Sources
- DrugPatentWatch